Cyprumed GmbH Tech Reaches Clinic; MSD Starts Phase I, Milestone Triggered

Cyprumed said MSD initiated a Phase I trial of a peptide formulated with Cyprumed’s oral delivery tech, triggering a milestone payment under their 2025 license deal that allows up to $493M in milestones.Material DetailsContext by AI AnalystThis is an early-stage clinical validation of Cyprumed’s or…